|
Feb 14
|
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
|
|
Feb 14
|
Is Novartis AG (NVS) the Best Foreign Dividend Stock to Buy According to Analysts?
|
|
Feb 14
|
Health Canada approves Novartis’ Fabhalta for PNH with haemolytic anaemia
|
|
Feb 12
|
Abcuro secures $200m as it eyes approval for rare muscle disease drug
|
|
Feb 11
|
Sector Update: Health Care Stocks Fall in Late Afternoon Trading
|
|
Feb 11
|
Top Midday Stories: Apple, Alibaba Shares Rise on AI Partnership News; Fidelity National Shares Fall After Q4 Revenue Miss
|
|
Feb 11
|
Novartis signs agreement to acquire Anthos for $925m upfront
|
|
Feb 11
|
Novartis Strikes Up to $3.1 Billion Deal to Buy Anthos Therapeutics
|
|
Feb 11
|
Novartis pays $925M to reel in a startup it helped launch
|
|
Feb 11
|
Novartis buys Blackstone's Anthos for up to $3.1 billion
|
|
Feb 11
|
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
|
|
Feb 10
|
Is Novartis AG (NVS) The Best Annual Dividend Stock To Buy Now?
|
|
Jan 3
|
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
|
|
Jan 3
|
Positive data could expand use of Novartis’ gene therapy for SMA
|
|
Dec 31
|
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
|
|
Dec 31
|
Here's Why Novartis (NVS) is a Strong Growth Stock
|
|
Dec 31
|
Novartis’ Gene Therapy Shows Promise in Treating SMA
|
|
Dec 31
|
Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint
|
|
Dec 30
|
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
|
|
Oct 5
|
Novartis AG (NVS): Driving Long-Term Growth with Strong Pipeline and Innovative Products
|